Ensartinib

Unassigned

New Medicines

Advanced or recurrent ALK-rearranged non-small cell lung cancer (NSCLC), previously untreated

Information

New molecular entity
Xcovery
Xcovery

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Anaplastic lymphoma kinase (ALK) inhibitor
In 2015, approximately 31,700 people were diagnosed with NSCLC in England. About 5% of all non-small cell lung cancer patients are diagnosed ALK-positive, equating to ~1,500 people in England.[1,2]
Advanced or recurrent ALK-rearranged non-small cell lung cancer (NSCLC), previously untreated
Oral